Debiopharm Announces Oncology Research Advancements at AACR 2022 for Novel Cancer Compounds and Drug Delivery Technologies
By asianet
Pre-clinical & clinical exploratory poster presentations to highlight oncology results with Debio 0123, xevinapant, and Multilink[TM] technology for antibody drug conjugates Debiopharm, (www.debiopharm.com/debiopharm-international/) an oncology and infectious disease focused biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including Debio 0123 (Selective WEE1 inhibitor), clinical exploratory results for xevinapant (IAP inhibitor), … Continued